HTB South

World AIDS 21 Durban 2016

21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

Once-daily raltegravir at last available: 48 week results from ONCEMRK study

Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

Efavirenz associated with suicide risk in analysis from START study

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women

High death rates among HIV positive women postpartum accessing ARVs

Higher rates of eye complications in HIV positive people on ART

Sub-Saharan African countries moving quickly to recommend “Treat All”

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms